

January 25, 2024

News Release

Company: Olympus Corporation
Stefan Kaufmann, Director, Representative Executive Officer, President and CEO
(Code: 7733, Prime, Tokyo Stock Exchange)
Contact: Takaaki Sakurai, Vice President, Investor Relations
TEL: +81-3-3340-2111

(Updated) (Progress of disclosure matters) Notice Regarding Completion of Acquisition of Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd. (to make it a subsidiary)

Olympus Corporation ("Olympus") hereby announces that there have been corrections made to the above-mentioned disclosure material released on January 24, 2024. We have revised a part of a sentence as follows. The correction is underlined.

1. Reason for correction

Olympus has plans to acquire all of the outstanding shares of Taewoong Medical Co., Ltd. ("Taewoong Medical"), but as of January 24, 2024, it has acquired 99.6% of outstanding shares. There is one remaining shareholder and we expect to acquire the remaining shares in the future. The impact on the acquisition amount is immaterial.

2. Details of correction

(Before correction)

Olympus Corporation ("Olympus") hereby announces that as of January 24, 2024 it has completed procedures to acquire Taewoong Medical Co., Ltd. (headquartered in the Korea), a medical device company. The acquisition was originally announced in the timely disclosure "Notice Regarding Acquisition of Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd. (to make it a subsidiary)" dated February 24, 2023 and "(Change of Disclosure Matters) Notice Regarding Acquisition of Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd. (to make it a subsidiary)" dated June 19, 2023.

(After correction)

Olympus Corporation ("Olympus") hereby announces that as of January 24, 2024 it has completed acquisition of 99.6% of the shares of Taewoong Medical Co., Ltd. (headquartered in the Korea), a medical device company. The acquisition was originally announced in the timely disclosure "Notice Regarding Acquisition of Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd. (to make it a subsidiary)" dated February 24, 2023 and "(Change of Disclosure Matters) Notice Regarding Acquisition of Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd. (to make it a subsidiary)" dated June 19, 2023.